LANCASTER, CA, September 6, 2005 – SimulationsPlus, Inc. (AMEX: SLP), today announced that John DiBella, M.S., formerly a life sciences product manager for the Company, will join the marketing and sales team as a field representative effective immediately. The addition of Mr. DiBella represents the second full-time person to be added to the marketing and sales department this past year.
Ron Creeley, vice president of marketing and sales, said: “John has been the product manager and primary scientist on the DDDPlus™ development project for the past two years and has also been involved with our GastroPlus™ product as a major participant in contracted studies. His knowledge of the Simulations Plus software offerings will complement our existing approach of having our senior scientists perform exhibits and customer visits, expanding our ability to reach more of the industry in a timely manner.”
John DiBella said: “Although I've enjoyed the software development side of the business, I believe I can offer even more to the Company as a field representative. I’m looking forward to meeting more of our customers and demonstrating how the outstanding tools developed by Simulations Plus can assist them in bringing their new products to market faster and more efficiently.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company’s Words+ subsidiary produces assistive technology and communication devices for persons with disabilities. The Company also produces a line of educational simulation software under the umbrella name FutureLab™, which is based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California. For more information, visit our Web sites at www.simulations-plus.com and www.words-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: the ability of the Company to continue to book revenues and earnings in accordance with existing accounting standards, the ability of the Company to maintain its competitive advantage, the general economics of the disability and pharmaceutical industries, the ability of the Company to attract and maintain sufficient scientific and technical staff to sustain its R&D and customer support functions, and a sustainable market. Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports as filed with the Securities and Exchange Commission.
For further information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA
93534-7059 USA
www.simulations-plus.com
CONTACT: investor relations:
Contact: Renee Bouche